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glands and tumor cells. Negligible androgen levels prevent stimulation of the intracellular receptor in the tumor cell, reducing
PSA synthesis and growth factors.
Objectives. To demonstrate the therapeutic beneﬁts and tolerance to abiraterone in elderly patients with metastatic castration-
resistant prostate cancer.
Methods. 82 year oldman, diagnosedwithprostate adenocarcinoma in 2005 (75 year old), PSA23, Gleason 6, T2b. Received complete
androgen deprivation therapy alone (anti-androgen and GnRH agonist), follow-up examination showed PSA 0,04 decline in 2006,
then progression to PSA 19,4 and bone scan suggestive of pelvic bone metastasis (2011). Discontinued treatment with anti-
androgen. PSA rise to 43.74 in January 2012, 10mg/24h prednisone prescribed. Follow-up showed PSA rise to 61 and alkaline
phosphatase 300 in August 2012. Bone scan suggested metastasis in iliac and sacrum bone. Patient refers mild pain in rest
and moderate pain while moving, no other symptoms associated. Karnosfky 95%, the CT extension study showed large bone
metastatic spread andno visceral or lymphnode involvement. Follow-up showed PSA 140, alkaline phosphatase 501, testosterone
level less than3ng/dl inOctober 2012. Abiraterone acetate 1000mgdaily andprednisone 5mgBIDprescribed. Zoledronic acid 4mg
iv/28 days and calcium and vitamin D oral. Pain management with oxycodone–naloxone 20/10/12h and ibuprofen 600mg/12h.
Results. Follow-up showed decline of PSA 27, alkaline phosphatase 300 and pain control improvement with no effect on blood
test results including liver function (normal hepatic enzymes level) in February 2013 (4 months after treatment start).
Conclusions. Abiraterone demonstrates its feasibility as therapeutic choice for elderly patients due to good tolerance.
http://dx.doi.org/10.1016/j.rpor.2013.03.469
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Introduction. Clinical evidences support dose escalation radiotherapy for unfavorable prostate cancer (PCa). To achieve it, we
combine Ir-192 High Dose Rate Brachytherapy (HDR-BT) with External Beam Radiotherapy (EBRT).
Purpose. Evaluation of acute urinary and intestinal toxicity during the following 6 months after treatment. Since almost all
patients were under androgen deprivation therapy (ATD), sexual toxicity has not been analyzed.
Methods. Between August 2010 and May 2012, 67 patients with intermediate/high risk PCa were treated. Median age: 75 (62–82).
Median follow-up: 14 months (6–29). Five patients had previous TURP and 3 had previous adenomectomy. EBRT administration
was 200 cGy/fraction, 5/week. Median needles used for HDR-BT procedure was 18 (12–27). If seminal vesicles involvement (21
patients), a single fraction of 9–9.5Gy HDR-BT plus 60Gy EBRT to pelvis and/or prostate-vesicles, was administrated. When
seminal vesicles were not inﬁltrated (46 patients), a single fraction of 15Gy HDR-BT plus 46Gy EBRT to pelvis or prostate-
vesicles. Sixty-one patients included ATD for 6 months in intermediate (24 patients) and 12–36 months in high risk PCa (37
patients). Toxicity evaluated following RTOG/EORTC criteria.
Results. After one month: 18 patients (26.8%) presented urinary toxicity; 16 G1 cases (dysuria and/or urgency), 1 G2 case (nocturia)
and 1 G4 case (complete urinary retention). Three patients presented intestinal G1 toxicity (diarrhea and/or mild bleeding). After
three months: 17 patients (25.3%) presented urinary toxicity; 13 G1 cases, 3 G2 cases and only one G4. Four G1 intestinal toxicity
cases were observed. After six months: 17 patients (25.3%) presented urinary toxicity; 10 G1 cases, 6 G2 cases, and 1 G4 case. Only
one patient presented G1 intestinal toxicity.
Conclusion. We found acceptable acute toxicity results. Main symptoms were dysuria and nocturia, most of them Grade 1. Only
three urinary G4 cases observed along the analyzed period. Intestinal toxicity cases were few and mild.
http://dx.doi.org/10.1016/j.rpor.2013.03.470
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Introduction. Recent publications have indicated that the ˛/ˇ ratio for prostate carcinoma is much lower than previously estab-
lished, suggesting that these tumours are much more sensitive to the dose administered per fraction. We do not know if the
hypofractionated treatment provides clinical beneﬁt in the treatment of prostate tumours.
Purpose. Assessment of the acute toxicity in patients diagnosed with prostate carcinoma and treated with hypofractionated
radiotherapy.
Methods and material. Between January 2012 and May 2012, 78 men were treated at the Hospitalary Radiophysics Unit of the
Hospital Complex of Jaén with ages comprised between 46 and 78 years old (average 68.3 years old), KPS 90-100%. They were
diagnosed with prostate adenocarcinoma, PSA between 4 and 188ngr/ml (average 16.39), Gleason 6 (56.5%) – 7 (23%) – 8 (9%) – 9
(5%) –others (6.5%), clinical stage T1c (65.4%), T2 (19.2%), T3 (15.4%). 78% of the cases were treated with androgen deprivation.
